

1 **A phase 1/2 randomized, double-blinded, placebo controlled ascending dose trial to assess**  
2 **the safety, tolerability and immunogenicity of ARCT-021 in healthy adults**

3  
4 Jenny G. Low, M.R.C.P., M.P.H., Ruklanthi de Alwis, M.P.H., Ph.D., Shiwei Chen, Ph.D.,  
5 Shirin Kalimuddin, M.R.C.P., M.P.H., Yan Shan Leong, B.Sc., Tania Ken Lin Mah, B.Sc.,  
6 Natalene Yuen B.Sc., Hwee Cheng Tan, Summer L Zhang M.Sc., Jean X.Y. Sim, M.R.C.P.,  
7 Yvonne F.Z. Chan, M.R.C.P., Ayesa Syenina, Ph.D., Jia Xin Yee, B.Sc., Eugenia Z. Ong, Ph.D.,  
8 Rose Sekulovich, Ph.D., Brian B. Sullivan, Ph.D., Kelly Lindert, M.D., Sean B. Sullivan, Ph.D.,  
9 Pad Chivukula, Ph.D., Steven G. Hughes M.B.,B.S., M.B.A., F.R.C.P., Eng Eong. Ooi, B.M.,  
10 B.S., Ph.D.

11  
12 Correspondence to:

13 Steven G Hughes

14 Arcturus Therapeutics, Inc., 10628 Science Center Drive, Suite 250, San Diego, CA92121, USA.

15 Email: [drstevehughes@gmail.com](mailto:drstevehughes@gmail.com)

16 **Abstract**

17 *Background*

18 The pandemic of coronavirus disease-19 (Covid-19) continues to afflict the lives and livelihoods  
19 of many as global demand for vaccine supply remains unmet.

20

21 *Methods*

22 Phase 1 of this trial (N=42) assessed the safety, tolerability and immunogenicity of ascending  
23 levels of one-dose ARCT-021, a self-amplifying mRNA vaccine against Covid-19. Phase 2  
24 (N=64) tested two-doses of ARCT-021 given 28 days apart. Both young and older adults were  
25 enrolled. The primary safety outcomes were local and systemic solicited adverse events (AEs)  
26 reported immediately and up to 7 days post-inoculation and unsolicited events reported up to 56  
27 days after inoculation. Secondary and exploratory outcomes were antibody and T cell responses  
28 to vaccination, respectively.

29

30 *Results*

31 ARCT-021 was well tolerated up to one 7.5 µg dose and two 5.0 µg doses. Local solicited AEs,  
32 namely injection-site pain and tenderness, as well as systemic solicited AEs, such as fatigue,  
33 headache and myalgia, were more common in ARCT-021 than placebo recipients, and in  
34 younger than older adults. Seroconversion rate for anti-S IgG was 100% in all cohorts except for  
35 the 1 µg one-dose in younger adults and the 7.5 µg one-dose in older adults, which were each  
36 80%. Neutralizing antibody titers increased with increasing dose although the responses  
37 following 5.0 µg and 7.5 µg ARCT-021 were similar. Anti-S IgG titers overlapped with those in  
38 Covid-19 convalescent plasma. ARCT-021 also elicited T-cell responses against the S  
39 glycoprotein.

40

41 *Conclusion*

42 Taken collectively, the favorable safety and immunogenicity profiles support further clinical  
43 development of ARCT-021.

44

## 45 **Introduction**

46

47 The coronavirus disease 2019 (Covid-19) pandemic, caused by the severe acute respiratory  
48 syndrome coronavirus-2 (SARS-CoV-2), has devastated lives globally<sup>1</sup>. Accelerated vaccine  
49 deployment has started to reverse this trend<sup>2,3</sup>. The most effective vaccines have been mRNA  
50 vaccines<sup>4-6</sup>. A newer synthetic mRNA platform - self-amplifying RNA (sa-mRNA) - may have an  
51 added advantage<sup>7,8</sup>; *in situ* mRNA amplification may allow for smaller doses to be administered,  
52 stretching the reach of limited vaccine supply to greater number of people<sup>9</sup>. However, there  
53 remains a paucity of data that informs on the safety and immunogenicity of such a vaccine  
54 construct.

55

56 We conducted a first-in-human clinical trial in healthy adults to evaluate the safety, tolerability  
57 and immunogenicity of ARCT-021, a self-transcribing and replicating mRNA (STARR<sup>TM</sup>)  
58 vaccine candidate for the prevention of Covid-19. The mRNA is a replicon that comprises the  
59 Venezuelan equine encephalitis virus (VEEV) genome in which the structural genes have been  
60 replaced with the SARS-CoV-2 full-length spike (S) gene, and formulated with the proprietary  
61 LUNAR<sup>®</sup> lipid nanoparticle (LNP). Translation of the replicon produces a multi-protein replicase  
62 complex that amplifies a subgenomic mRNA for elevated expression of the S glycoprotein.  
63 Preclinical experiments showed that a single dose of ARCT-021 elicited strong Th1-predominant  
64 humoral and cellular immune responses against the S protein that protected K-18 human ACE2  
65 transgenic mice from lethal SARS-CoV-2 challenge<sup>10</sup>. Here we report the findings from the Phase  
66 1/2 clinical trial.

67

## 68 **Methods**

69

### 70 Trial design, participants and oversight

71 ARCT-021-01 is a randomized, double-blinded, placebo (0.9% saline) controlled study to assess  
72 the safety, tolerability and immunogenicity of different dose levels of ARCT-021. The primary  
73 endpoint was safety and tolerability; secondary and exploratory endpoints were antibody and T-  
74 cell responses. The trial was conducted at the Singapore Health Services (SingHealth)  
75 Investigational Medicine Unit, following approvals by the SingHealth Centralized Institutional

76 Review Board (CIRB F/2020/2553) and the Singapore Health Sciences Authority. The trial was  
77 registered in [clinicaltrials.gov](https://clinicaltrials.gov) (NCT04480957). A safety review committee reviewed data  
78 regarding safety and overall trial progress, including dose escalation decisions.

79  
80 The trial comprised two overlapping parts and evaluated a range of doses of ARCT-021 versus  
81 placebo given as one- or two-dose administration to younger (21 to 55 years) and older (56 to 80  
82 years) adult participants. In the Phase 1 part, a one-dose administration (dose levels 1.0 µg, 5.0 µg,  
83 7.5 µg and 10 µg ARCT-021 versus placebo) was given as an intramuscular (IM) injection to  
84 younger adults (Cohorts A, B, D1 and C, respectively) and a single dose (7.5 µg ARCT-021 versus  
85 placebo) was given to older adults (Cohort D2). In the Phase 2 part, two-dose administrations of  
86 3.0 µg and 5.0 µg ARCT-021 versus placebo separated by 28 days were administered to younger  
87 participants (Cohorts F and E) and older participants (Cohorts H and G), respectively. All  
88 participants were followed up for 56 days after the last study vaccine administration.

89  
90 Full lists of the inclusion and exclusion criteria are provided in the protocol. Written informed  
91 consent was provided by all the participants before enrollment.

92  
93 Arcturus Therapeutics, Inc. was the regulatory sponsor of the trial. Both Arcturus Therapeutics  
94 and Duke-NUS Medical School co-designed the clinical trial and were responsible for the  
95 collection, analysis, and interpretation of the data and for the writing of the report. Arcturus  
96 Therapeutics and the corresponding author had full access to all the data in the trial and had final  
97 responsibility for the decision to submit the manuscript for publication. All the trial data were  
98 available to all the authors. Clinical monitoring, pharmacovigilance, and data management were  
99 performed by the Contract Research Organization, CTI.

100

#### 101 Trial procedures

102 Participants were randomized after completing all screening assessments and eligibility criteria.  
103 Phase 1 participants were randomized 5:2 to receive ARCT-021 or placebo. Phase 2 participants  
104 were randomized 3:1 to receive ARCT-021 or placebo. All participants were administered 0.5-ml  
105 injections of ARCT-021 or placebo into the lateral aspect of the deltoid muscle of the non-  
106 dominant arm while the second injection (Phase 2 cohorts) was administered into the contralateral

107 arm. All participants were observed for a minimum of 4 hours after the injection. Blood samples  
108 were obtained for safety and immunogenicity assessments according to protocol schedule. The  
109 initial planned single doses to be tested were 1.0 µg, 5.0 µg, 10 µg and 20 µg in the single dose  
110 cohorts; The final tested doses were 1.0 µg, 5.0 µg, 7.5 µg and 10 µg in the single dose cohorts and  
111 3.0ug and 5.0ug in the two dose cohorts.

112

### 113 Vaccine and placebo

114 ARCT-021 was presented as a sterile, frozen, aqueous formulation with 0.2 mg/mL of mRNA-  
115 2002 and as a 1.0 mL fill (0.2 mg/1 mL) in 2-mL Type I glass vials, stored frozen at -70°C (+/-  
116 10°C). It is a white to off-white liquid when thawed with a nominal pH of 8.0 and osmolality of  
117 approximately 1300 mOsm/kg. The placebo was 0.9% sterile saline provided by the study center.

118

### 119 Safety Assessments

120 Local and systemic solicited and unsolicited AEs were recorded daily by the participant in a  
121 symptom diary for at least 7 days and up to 14 days post vaccination if any events persisted beyond  
122 Day 7. The symptom diaries were reviewed by site staff at study visits for up to 14 days post each  
123 injection. Injection site was inspected at all visits up to Day 15 (for first injection)/Day 43 (for  
124 second injection) or until resolution of local reactogenic event(s). Unsolicited events were  
125 collected at all visits and for the duration of study participation.

126

### 127 Immunogenicity

128 IgM, IgA and IgG against full-length recombinant S protein were assessed using a Luminex  
129 immuno-assay. IgG against the S protein subdomains (RBD, NTD and S2) were also measured for  
130 5.0µg, 7.5µg single and 5.0µg expansion cohorts. Neutralizing antibody was measured using  
131 plaque reduction neutralization test (PRNT), with a clinical SARS CoV-2 isolate (hCoV-  
132 19/Singapore/2/2020), and the serum titer that neutralizes 50% of the virus inoculum (PRNT<sub>50</sub>)  
133 was calculated as previously described<sup>11</sup>. SARS-CoV-2 specific T-cell responses were assessed  
134 using flow cytometry (FC) and IFNγ ELISPOT assay following stimulation with overlapping S  
135 protein peptide pools.

136

### 137 Statistical Analysis

138 No formal sample size calculation was performed. Based on experience from previous studies with  
139 other RNA based therapies, the chosen cohort sizes were considered sufficient to meet the  
140 objectives of the study while minimizing unnecessary participant exposure. For analysis of safety  
141 and humoral immunogenicity, placebo participants were pooled by age group and number of doses  
142 administered as follows: A to D1 pooled, E and F pooled, G and H pooled. D2 was the only single  
143 dose older adult cohort so D2 placebos were not pooled. For humoral immunogenicity, confidence  
144 intervals of the geometric means were calculated with the Student's t distribution on log-  
145 transformed data. Seroconversion was defined as at least a 4-fold increase in antibody titer from  
146 baseline.

147

## 148 **Results**

### 149 Trial Participants

150 In total, 169 healthy volunteers were screened, with 106 participants randomized and injected. The  
151 distribution of participants by cohort is shown in Figure 1. All participants received assigned doses  
152 of ARCT-021. All enrolled participants completed the planned study scheduled trial visits. A  
153 summary of demographic characteristics by treatment assignment is presented in Table 1.

154

### 155 Safety

156 A summary of solicited local and systemic adverse events (AE) is presented in Figures 2 and 3.  
157 ARCT-021 was generally well tolerated up to the 7.5 µg dose. The 10 µg dose was associated with  
158 more local and systemic solicited AE, including grade 3 severity. Although the study stopping  
159 rules were not met, the protocol was amended to remove further dose escalation. A younger  
160 (Cohort D1) and older adult (Cohort D2) one-dose cohorts at the 7.5 µg dose level were added  
161 following safety review. A single serious adverse event due to cellulitis of the foot in a placebo  
162 recipient following an insect-bite was reported. It was medically attended and resolved after two  
163 days. All participants in the 2-dose cohorts completed the vaccinations without any delay.

164

### 165 *Solicited Treatment Emergent Adverse Events*

#### 166 Local reactions

167 Sixty-nine (88.5%) participants who received ARCT-021 reported local solicited AEs, as  
168 compared to 21.4% of placebo-treated participants (Figure 2). These included injection site

169 tenderness and pain in 73.1% and 60.3% of participants, respectively. In the two-dose younger  
170 adult cohorts, local solicited AE occurred in 11(91.7%) following the first dose at both 5.0 µg and  
171 3.0 µg and in 11 (91.7%) and 12 (100%), respectively, following the second dose. In older adults,  
172 local solicited events occurred in 8 (66.7%) and 9 (75%) following the first dose and in 8 (66.7%)  
173 and 10 (83.3%) following the second dose in the 5.0 µg and 3.0 µg dose cohorts, respectively. A  
174 higher proportion of participants experienced moderate grade injection site tenderness with the  
175 second dose. At the same dose level, a higher proportion of younger than older adults experienced  
176 ≥ grade 2 solicited AE. There was no reported injection site erythema or swelling. There was one  
177 grade 3 injection site pain at the 10µg dose. There were no grade 4 local reactions and no  
178 discernable dose relationship.

179

### 180 Systemic Reactions

181 Overall, 62.8% of participants who received ARCT-021 reported a systemic solicited AE as  
182 compared to 46.4% amongst the placebo recipients (Figure 3). The most common events were  
183 fatigue (50.0%), headache (34.6%), myalgia (28.2%), chills (25.6%), and fever (14.1%) and were  
184 more common in younger than older adults. Systemic AEs were primarily mild or moderate with  
185 no grade 4 events reported. Grade 3 solicited events occurred primarily in the 10 µg dose cohort.  
186 Two grade 3 events (fatigue and arthralgia) occurred in a single participant following the second  
187 dose in the 5.0 µg older adult cohort. Severity of systemic AEs trended with dose. Most systemic  
188 AEs commenced within 1 to 2 days after vaccination and resolved or reduced in severity within 7  
189 days.

190

### 191 *Unsolicited Systemic Treatment Emergent Adverse Events*

192 Unsolicited AEs are summarized in Supplementary Table 1. In general, more participants  
193 vaccinated with ARCT-021 reported unsolicited AEs after vaccination. Five were severe,  
194 occurring primarily in the 10 µg dose cohort. These events occurred on the day after injection and  
195 resolved or improved in severity within 2 days after onset. One participant in older adult 3.0 µg  
196 two dose cohort (F) experienced grade 3 transaminitis 57 days after the last dose of ARCT-021.  
197 This event was classed as unlikely related by the Investigator and resolved after 18 days. No severe  
198 events occurred in placebo treated participants.

199

200 *Abnormal hematological and biochemical findings*

201 There appeared to be a dose-related trend for  $\geq$ grade 2 lymphopenia with 0%, 25%, 26.5%, 30.0%  
202 and 40.0% of participants affected at the 1.0  $\mu$ g, 3.0  $\mu$ g, 5.0  $\mu$ g, 7.5  $\mu$ g and 10  $\mu$ g dose levels,  
203 respectively. Onset of lymphopenia occurred within 24 hours after injection and resolved  
204 uneventfully, generally within a day. The incidence was similar following the first (14 of 78  
205 participants [17.9%]) and second dose (10 of 48 participants [20.8%]). Three of 48 (6.3%)  
206 participants had  $\geq$  grade 2 lymphopenia following both the first and second injection. There was  
207 no trend for increased severity following the second injection. The incidence was similar in older  
208 (24.1%) and younger adults (26.5%). There were 10 (12.8%) Grade 2 neutropenia events, the  
209 incidence of which was higher in older (17.2%) than younger (10.2%) adults. All neutropenic  
210 episodes were asymptomatic, resolved spontaneously and did not result in any sequelae.

211  
212 Post-baseline elevations of ALT occurred in 5 ARCT-021 treated participants (Supplementary  
213 Table 3). Two of these participants had ALT elevation at screening, which had normalized at Day  
214 1. No elevations of hepatic enzymes were observed in placebo participants. There were no other  
215 notable laboratory abnormalities.

216

217 Immunogenicity

218

219 *SARS-CoV-2 Binding Antibodies and Neutralization Response*

220 Seroconversion rate for anti-S IgG was 100% in all cohorts except for the one-dose younger adult  
221 cohort A (1  $\mu$ g) and the one-dose older adult cohort D2 (7.5  $\mu$ g), which were both 80%. The IgG  
222 response increased with increasing dose (Fig 4A, Table S5 and S6), although there was a trend for  
223 better responses at the 5.0  $\mu$ g dose than at the 7.5  $\mu$ g dose in older adults after a single dose  
224 (compared at Day 29 in the two-dose cohorts). With the exception of the 1  $\mu$ g dose, S-binding IgG  
225 titers overlapped with the range of antibodies in Covid-19 convalescent plasma (Fig. 4A). Vaccine-  
226 induced IgG antibodies bound the various S protein subdomains, including the RBD, NTD and the  
227 highly conserved S2 (Fig. 4B). PRNT<sub>50</sub> titers increased with increasing dose, while the responses  
228 were similar following one-dose of 5.0  $\mu$ g and 7.5  $\mu$ g. At doses  $\geq$  3  $\mu$ g, PRNT<sub>50</sub> titers were within  
229 the range observed in convalescent sera from patients with mild to moderate Covid-19<sup>10</sup>.

230



### 231 *SARS-CoV-2 T-Cell Response*

232 T-cell responses were observed on both ELISPOT and ICS in response to stimulation with six  
233 peptide pools covering the entire S glycoprotein (Fig. S1). IFN $\gamma$  ELISPOT responses were  
234 generally maximal at Day 15, and were similar at the 5.0  $\mu$ g and 7.5  $\mu$ g dose in younger adults  
235 (Fig. 4D-E and Fig. S2). Responses in the 5.0  $\mu$ g older adult cohort peaked after the second dose  
236 (Fig. 4E and Fig. S3). IFN $\gamma$  ELISPOT responses were generally higher in younger adults (Fig. 4D-  
237 E). CD4 T-cell IFN- $\gamma$  responses as measured by ICS showed the greatest values at Day 29 in the  
238 1.0  $\mu$ g and 5.0  $\mu$ g single dose cohorts (Fig. S5). CD4 T-cell IFN- $\gamma$  responses were generally greater  
239 in older adults than younger adults at the 5.0  $\mu$ g and 7.5  $\mu$ g doses and were similar between the  
240 two age groups at the 3  $\mu$ g dose. A further increase in CD4 T-Cell IFN- $\gamma$  responses following  
241 second dose was only seen in the 5.0  $\mu$ g younger adults. At all tested doses, the CD4 T-cell  
242 responses were Th1 dominant (Fig. S6). The CD8 T-cell IFN- $\gamma$  cytokine responses by ICS showed  
243 the highest values at Day 29 in the 5.0  $\mu$ g single dose cohort. CD8 IFN- $\gamma$  responses in the older  
244 adult cohorts were higher than the responses observed in the younger adult cohorts at the same  
245 dose (Fig. S4). There was no further increase in CD8 T-cell IFN- $\gamma$  responses following the second  
246 dose (Fig. S4).

247

### 248 **Discussion**

249

250 The shortage in Covid-19 vaccine supply continues to affect global recovery from this pandemic.  
251 A dose-sparing sa-mRNA vaccine could thus contribute to addressing this shortage.

252

253 We found an overall favorable safety profile up to 7.5 $\mu$ g dose. Over 96% of all AEs were either  
254 mild or moderate. Transient lymphopenia and neutropenia, possibly due to innate immune driven  
255 redistribution of lymphocytes<sup>12</sup> were observed, similar to other mRNA vaccines<sup>13,14</sup>.

256

257 ARCT-021 is also immunogenic. Anti-S IgG antibody levels were within the range of convalescent  
258 plasma, even after just one-dose. Vaccination also produced anti-S antibody of different types –  
259 IgM and IgA – in addition to IgG. These antibodies can elicit Fc-mediated functions, such as  
260 complement activation, antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis, as  
261 well as protect the mucosa. Indeed, recent reports suggest that Covid-19 can be prevented despite

262 low levels<sup>15</sup> or even absence of neutralizing antibodies<sup>16</sup>. Even antibodies that enhance SARS-  
263 CoV-2 infection *in vitro* protected non-human primates (NHPs) against SARS-CoV-2 challenge<sup>17</sup>.  
264 Finally, onset of mRNA vaccine-mediated protection against Covid-19 was associated with the  
265 development of anti-S antibodies that showed ADCC activity, along with S-reactive T cells,  
266 without neutralizing antibodies<sup>11,18</sup>. These findings collectively indicate that other functions of  
267 antibodies besides virus neutralization play key roles in protecting against Covid-19.

268  
269 Although a single dose of ARCT-021 was immunogenic, the second dose did not boost antibody  
270 titers dramatically. This may be due to three reasons: Firstly, the one-month interval between prime  
271 and boost may be too short for maximal boosting; secondly, we have not modified the S gene  
272 based on the immunogenicity and efficacy observed in our preclinical study<sup>10</sup> and; finally, we  
273 wanted to ensure that our CD8 T cell response would be directed against the native S since, at the  
274 time when ARCT-021 development began, the CD8 T cell epitopes had not been fully mapped.

275  
276 Our intention to elicit appreciable CD8 T cell responses with vaccination was driven by the  
277 collective body of evidence indicating the importance of cellular immunity in preventing Covid-  
278 19. Pre-clinical studies on ARCT-021 showed that vaccine-induced protection against SARS-  
279 CoV-2 was mediated primarily by CD8 T-cells rather than B cells<sup>10</sup>. In NHPs, cellular immunity  
280 compensated for low antibody levels in protecting against SARS-CoV-2 infection<sup>19</sup>. Clinically,  
281 delayed T but not B cell responses were associated with severe disease<sup>20</sup>. Recognition of epitopes  
282 spanning the S protein by CD8 T cells could also protect against neutralizing antibody-evading  
283 variants of concern (VOC)<sup>21</sup>; several such VOCs are presently spreading globally and will be the  
284 main challenge for any new Covid-19 vaccines<sup>22</sup>. Indeed, T cell responses may underpin the  
285 sustained efficacy of mRNA vaccines against these VOCs<sup>23</sup>.

286  
287 Our findings contrast with the phase 1 trial finding of another sa-mRNA vaccine<sup>24</sup>. The reasons  
288 for the different outcomes are uncertain currently although there are differences in both the S gene  
289 sequence and vaccine formulation<sup>10,25</sup>. Further investigations to understand the underpinnings of  
290 different immunogenicity outcome could be informative on future sa-mRNA vaccine design.

291

292 Taken collectively, the favorable safety and immunogenicity profiles support further clinical  
293 development of ARCT-021. A larger multi-center phase 2 clinical trial (NCT04668339) recruiting  
294 ~600 healthy adult volunteers is ongoing to guide a subsequent phase 3 clinical trial.

295

## 296 **Author affiliations**

297 From Singapore General Hospital (JGL, SK, JXYS, YFZC); Duke-National University of  
298 Singapore Medical School (JGL, RdA, SC, SK, YSL, TKLM, NY, HCT, SLZ, AS, JXY, EZO,  
299 EEO); Nanyang Technological University (NY); Arcturus Therapeutics (RS, BBS, KL, SBS, PC,  
300 SGH).

301

## 302 **References**

- 303 1. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health  
304 concern. *Lancet* 2020 (In eng). DOI: 10.1016/S0140-6736(20)30185-9.
- 305 2. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide  
306 Mass Vaccination Setting. *N Engl J Med* 2021;384(15):1412-1423. DOI:  
307 10.1056/NEJMoa2101765.
- 308 3. Vasileiou E, Simpson CR, Shi T, et al. Interim findings from first-dose mass COVID-19  
309 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective  
310 cohort study. *Lancet* 2021;397(10285):1646-1657. DOI: 10.1016/S0140-6736(21)00677-  
311 2.
- 312 4. Bloom K, van den Berg F, Arbuthnot P. Self-amplifying RNA vaccines for infectious  
313 diseases. *Gene Ther* 2020. DOI: 10.1038/s41434-020-00204-y.
- 314 5. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-  
315 CoV-2 Vaccine. *N Engl J Med* 2021;384(5):403-416. DOI: 10.1056/NEJMoa2035389.
- 316 6. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA  
317 Covid-19 Vaccine. *N Engl J Med* 2020;383(27):2603-2615. DOI:  
318 10.1056/NEJMoa2034577.
- 319 7. Lundstrom K. Self-Replicating RNA Viruses for RNA Therapeutics. *Molecules*  
320 2018;23(12). DOI: 10.3390/molecules23123310.
- 321 8. Tews BA, Meyers G. Self-Replicating RNA. *Methods Mol Biol* 2017;1499:15-35. DOI:  
322 10.1007/978-1-4939-6481-9\_2.
- 323 9. Castillo JC, Ahuja A, Athey S, et al. Market design to accelerate COVID-19 vaccine  
324 supply. *Science* 2021;371(6534):1107-1109. (In eng). DOI: 10.1126/science.abg0889.
- 325 10. de Alwis R, Gan ES, Chen S, et al. A single dose of self-transcribing and replicating RNA-  
326 based SARS-CoV-2 vaccine produces protective adaptive immunity in mice. *Mol Ther*  
327 2021 (In eng). DOI: 10.1016/j.yymthe.2021.04.001.
- 328 11. Kalimuddin S, Tham CY, Qui M, et al. Early T cell and binding antibody responses are  
329 associated with Covid-19 RNA vaccine efficacy onset. *Med (N Y)* 2021 (In eng). DOI:  
330 10.1016/j.medj.2021.04.003.

- 331 12. Kamphuis E, Junt T, Waibler Z, Forster R, Kalinke U. Type I interferons directly regulate  
332 lymphocyte recirculation and cause transient blood lymphopenia. *Blood*  
333 2006;108(10):3253-61. DOI: 10.1182/blood-2006-06-027599.
- 334 13. Mulligan MJ, Lyke KE, Kitchin N, et al. Phase I/II study of COVID-19 RNA vaccine  
335 BNT162b1 in adults. *Nature* 2020;586(7830):589-593. DOI: 10.1038/s41586-020-2639-4.
- 336 14. Sahin U, Muik A, Derhovanessian E, et al. COVID-19 vaccine BNT162b1 elicits human  
337 antibody and TH1 T cell responses. *Nature* 2020;586(7830):594-599. DOI:  
338 10.1038/s41586-020-2814-7.
- 339 15. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive  
340 of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med* 2021 (In eng).  
341 DOI: 10.1038/s41591-021-01377-8.
- 342 16. Soresina A, Moratto D, Chiarini M, et al. Two X-linked agammaglobulinemia patients  
343 develop pneumonia as COVID-19 manifestation but recover. *Pediatr Allergy Immunol*  
344 2020;31(5):565-569. (In eng). DOI: 10.1111/pai.13263.
- 345 17. Li D, Edwards RJ, Manne K, et al. The functions of SARS-CoV-2 neutralizing and  
346 infection-enhancing antibodies in vitro and in mice and nonhuman primates. *bioRxiv* 2021  
347 (In eng). DOI: 10.1101/2020.12.31.424729.
- 348 18. Tauzin A, Nayrac M, Benlarbi M, et al. A single BNT162b2 mRNA dose elicits antibodies  
349 with Fc-mediated effector functions and boost pre-existing humoral and T cell responses.  
350 *bioRxiv* 2021 (In eng). DOI: 10.1101/2021.03.18.435972.
- 351 19. McMahan K, Yu J, Mercado NB, et al. Correlates of protection against SARS-CoV-2 in  
352 rhesus macaques. *Nature* 2021;590(7847):630-634. (In eng). DOI: 10.1038/s41586-020-  
353 03041-6.
- 354 20. Tan AT, Linster M, Tan CW, et al. Early induction of functional SARS-CoV-2-specific T  
355 cells associates with rapid viral clearance and mild disease in COVID-19 patients. *Cell Rep*  
356 2021;34(6):108728. (In eng). DOI: 10.1016/j.celrep.2021.108728.
- 357 21. Geers D, Shamier MC, Bogers S, et al. SARS-CoV-2 variants of concern partially escape  
358 humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees. *Sci*  
359 *Immunol* 2021;6(59) (In eng). DOI: 10.1126/sciimmunol.abj1750.
- 360 22. Garcia-Beltran WF, Lam EC, St Denis K, et al. Multiple SARS-CoV-2 variants escape  
361 neutralization by vaccine-induced humoral immunity. *Cell* 2021;184(9):2523. (In eng).  
362 DOI: 10.1016/j.cell.2021.04.006.
- 363 23. Andreano E, Rappuoli R. SARS-CoV-2 escaped natural immunity, raising questions about  
364 vaccines and therapies. *Nat Med* 2021;27(5):759-761. (In eng). DOI: 10.1038/s41591-021-  
365 01347-0.
- 366 24. Pollock KM, Cheeseman HM, Szubert AJ, et al. Safety and immunogenicity of a self-  
367 amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial.  
368 2021;PREPRINT.
- 369 25. McKay PF, Hu K, Blakney AK, et al. Self-amplifying RNA SARS-CoV-2 lipid  
370 nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. *Nat*  
371 *Commun* 2020;11(1):3523. (In eng). DOI: 10.1038/s41467-020-17409-9.
- 372

**Table 1. Demographic Characteristics of the Participants, According to Dose Cohort and Age Group\***

Cohort	Single Dose Cohorts							Two-Dose Cohorts					
	Age 21 - 55					Age 56 - 80		Age 21 - 55			Age 56 - 80		
	Cohort A 1µg	Cohort B 5µg	Cohort C 10µg	Cohort D1 7.5µg	Pooled Placebo Cohorts A to D1	Cohort D2 7.5µg	Cohort D2 Placebo	Cohort E 5µg	Cohort F 3µg	Pooled Placebo Cohorts E and F	Cohort G 5µg	Cohort H 3µg	Pooled Placebo Cohorts G and H
Number of Participants	5	10	5	5	10	5	2	12	12	8	12	12	8
Sex - n (%)													
Male	3 (60.0)	6 (60.0)	2 (40.0)	4 (80.0)	8 (20.0)	5 (100)	1 (50.0)	8 (66.7)	10 (83.3)	5 (62.5)	11 (91.7)	8 (66.7)	7 (87.5)
Female	2 (40.0)	4 (40.0)	3 (60.0)	1 (20.0)	2 (20.0)	0 (0)	1 (50.0)	4 (33.3)	2 (16.7)	3 (37.5)	1 (8.3)	4 (33.3)	1 (12.5)
Race - n (%)†													
Asian	5 (100)	10 (100)	5 (100)	4 (80.0)	10 (100)	5 (100)	2 (100)	11 (91.7)	10 (83.3)	7 (87.5)	12 (100)	12 (100)	7 (87.5)
White	0 (0)	0 (0)	0 (0)	1 (20.0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (8.3)	1 (12.5)	0 (0)	0 (0)	1 (12.5)
American Indian or Alaskan Native	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (8.3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Other	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (8.3)	0 (0)	0 (0)	0 (0)	0 (0)
Hispanic Ethnic Group – n (%)†	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Age (years) ‡													
Mean (SD)	35 (±9.17)	39.5 (±7.15)	41.4 (±12.48)	40.4 (±10.41)	33.5 (±8.72)	64 (±5.61)	61.5 (±6.36)	34.5 (±8.33)	38 (±9.34)	39.1 (±7.95)	62.3 (±4.63)	61.7 (±3.77)	63.3 (±5.70)


Cohort	Single Dose Cohorts						Two-Dose Cohorts						
	Age 21 - 55					Age 56 - 80	Age 21 - 55			Age 56 - 80			
Variable	Cohort A	Cohort B	Cohort C	Cohort D1	Pooled Placebo Cohorts A to D1	Cohort D2	Cohort D2 Placebo	Cohort E	Cohort F	Pooled Placebo Cohorts E and F	Cohort G	Cohort H	Pooled Placebo Cohorts G and H
	1µg	5µg	10µg	7.5µg		7.5µg		5µg	3µg		5µg	3µg	
Median [range]	32.0 [28-50]	40.0 [29-51]	44.0 [24-55]	47.0 [24-48]	34.5 [21-46]	64.0 [57-70]	61.5 [57-66]	35.5 [21-47]	35.0 [22-51]	37.0 [30-51]	62.0 [56-70]	61.5 [56-68]	64.5 [56-71]

Abbreviations: N = total number of subjects in each dose cohort; n = number of subjects contributing to the summary; SD = standard deviation

\*Percentages may not total 100 because of rounding

†Race and ethnic group were reported by the participant.

‡ The age of the participants was the age at the time of screening




**Figure 1. Enrolment and randomization of trial participants.**

Abbreviations: N = number of participants in the cohort; n = number of participants in each treatment group; OA = older adults (56-80 years); YA = younger adults (21-55 years).


Phase 1 – Single injection, escalating dose. Study duration 56 days post first injection.

Phase 2 – Two same dose injections, 28 days apart. Study duration 85 days post first injection.

### A. 21-55 yrs of age



### B. 56-80 yrs of age




**Figure 2. Local solicited adverse events.** Shown are the percentages of vaccinated participants reporting local solicited events. Data are represented for age groups, 21-55 years (Panel A) and 56-80 years (Panel B). Severity of local solicited Events are displayed as mild (green), moderate




(blue), severe (orange) or life-threatening (red). \*Note, injection site swelling and injection site redness were not reported. YA=Younger Adults (21-55); OA=Older Adults (56-80).


**A. 21-55 yrs of age**



**B. 56-80 yrs of age**



**Figure 3. Systemic solicited adverse events.** Percentage of systemic solicited events reported in vaccinated participants aged 21-55 years (Panel A) and 56-80 years (Panel B). Severity of systemic solicited Events are displayed as mild (green), moderate (blue), severe (orange) or life-threatening (red). YA=Younger Adults (21-55); OA=Older Adults (56-80).



**Figure 4. Antibody and T cell responses.** Shown are IgG reciprocal endpoint titers to SARS-CoV-2 whole ectodomain Spike using Luminex immune-Assay (Panel A). IgG reciprocal titers to the Spike sub-domains, i.e. receptor-binding domain (RBD), N-terminal binding domain (NTD) and domain 2 (S2) using Luminex immuno-assay is represented for selected cohorts and timepoints (Panel B). Antibody neutralization of live SARS-CoV-2 virus was measured using a BSL3 plaque reduction neutralization assay (PRNT) and represented as 50% neutralization titers (PRNT50) (Panel C). Cellular immunity and T cell responses in prime and prime-boost cohorts were measured using an interferon gamma (IFN $\gamma$ ) enzyme-linked immune absorbent spot (ELISPOT) assay and represented as spot-forming cells (SFC) per million PBMCs (Panel D and

E). Displayed ELISPOT results are cumulative responses of six peptide pools spanning the entire SARS-CoV-2 Spike. Peptide pool-specific responses presented in Fig. S2 and S3. For Panels A-C, the error bars display standard deviation around the GMT depicted by a horizontal bar. For Panels D and E, the whiskers display standard deviation (SD) around the mean (horizontal bar). Each dot represents an individual participant.

## Supplementary Appendix

**Table S1: Summary of Unsolicited Treatment Emergent Adverse Events According to Dose Cohort and Age Group**

Cohort	Single Dose							Two-Dose					
	Age 21 - 55					Age 56 - 80		Age 21 - 55			Age 56 - 80		
	Cohort A 1µg (N=5)	Cohort B 5µg (N=10)	Cohort C 10µg (N=5)	Cohort D1 7.5µg (N=5)	Pooled Placebo A to D1 (N=10)	Cohort D2 7.5µg (N=5)	Cohort D2 Placebo (N=2)	Cohort E 5µg (N=12)	Cohort F 3µg (N=12)	Pooled Placebo E and F (N=8)	Cohort G 5µg (N=12)	Cohort H 3µg (N=12)	Pooled Placebo G and H (N=8)
Any Unsolicited Event	4 (80.0)	7 (70.0)	5 (100.0)	4 (80.0)	5 (50.0)	5 (100.0)	0	8 (66.7)	8 (66.7)	6 (75.0)	12 (100.0)	8 (66.7)	3 (37.5)
Related	4 (80.0)	6 (60.0)	5 (100.0)	3 (60.0)	0	5 (100.0)	0	7 (58.3%)	8 (66.7%)	1 (12.5%)	9 (75.0%)	5 (41.7%)	1 (12.5%)
Severe	0	0	2 (40.0)	0	0	0	0	0	0	0	0	1 (8.3)	0
Life threatening	0	0	0	0	0	0	0	0	0	0	0	0	0
Any Serious Unsolicited Event	0	0	0	0	1 (10.0)	0	0	0	0	0	0	0	0
Related	0	0	0	0	0	0	0	0	0	0	0	0	0
Severe	0	0	0	0	0	0	0	0	0	0	0	0	0
Life-threatening	0	0	0	0	0	0	0	0	0	0	0	0	0
Any Unsolicited Event Leading to Withdrawal	0	0	0	0	0	0	0	0	0	0	0	0	0
Related	0	0	0	0	0	0	0	0	0	0	0	0	0
Severe	0	0	0	0	0	0	0	0	0	0	0	0	0
Life-threatening	0	0	0	0	0	0	0	0	0	0	0	0	0
Death	0	0	0	0	0	0	0	0	0	0	0	0	0

**Table S2: Medically Attended Events by Dose Cohort and Age Group**

Cohort	Single Dose							Two-Dose					
	Age 21 - 55					Age 56 - 80		Age 21 - 55			Age 56 - 80		
Event Term / n(%)	Cohort A 1µg (N=5)	Cohort B 5µg (N=10)	Cohort C 10µg (N=5)	Cohort D1 7.5µg (N=5)	Pooled Placebo Cohorts A to D1 (N=10)	Cohort D2 7.5µg (N=5)	Cohort D2 Placebo (N=2)	Cohort E 5µg (N=12)	Cohort F 3µg (N=12)	Pooled Placebo Cohorts E and F (N=8)	Cohort G 5µg (N=12)	Cohort H 3µg (N=12)	Pooled Placebo Cohorts G and H (N=8)
Cellulitis	0	0	0	0	1 (10.0)	0	0	0	0	0	0	0	0
Skin laceration	0	0	0	0	0	0	0	0	1 (8.3)	0	0	0	0
Fever	0	0	0	0	0	0	0	0	0	1 (12.5)	0	0	0
Fatigue	0	0	0	0	0	0	0	0	0	1 (12.5)	0	0	0
Diarrhoea	0	0	0	0	0	0	0	0	0	1 (12.5)	0	0	0
Vomiting	0	0	0	0	0	0	0	0	0	0	1 (8.3)	0	0
Nausea	0	0	0	0	0	0	0	0	0	0	0	1 (8.3)	0
Dizziness	0	0	0	0	0	0	0	0	0	0	1 (8.3)	1 (8.3)	0

**Table S3: Grade Shifts in Alanine Transaminase and Aspartate Transaminase in ARCT-021 Treated Participants**

		ALT				
		Post Vaccination				
		Normal	G1	G2	G3	G4
Baseline	Normal	72 (92.3)	4 (5.1)	0	1 (1.3)	0
	G1	0	1 (1.3)	0	0	0
	G2	0	0	0	0	0
	G3	0	0	0	0	0
	G4	0	0	0	0	0

AST				
Post Vaccination				
Normal	G1	G2	G3	G4
75 (96.2)	2 (2.6)	1 (1.3)	0	0
0	0	0	0	0
0	0	0	0	0
0	0	0	0	0
0	0	0	0	0

**Table S4: Total Number (%) of Events by Class of Event, Treatment Group and Severity – Safety Population**

Event Category	Number (%) of Events by Type and Severity							
	ARCT-021-01				Placebo			
	Grade 1/ Mild	Grade 2/ Moderate	Grade 3 / Severe	Total	Grade 1 / Mild	Grade 2/ Moderate	Grade 3/ Severe	Total
Any Event	387 (78.2)	91 (18.4)	17 (3.4)	495 (100.0)	66 (88.0)	9 (12.0)	0	75 (100.0)
Any Local Solicited Event	142 (28.7)	16 (3.2)	1 (0.2)	159 (32.1)	9 (12.0)	0	0	9 (12.0)
Any Systemic Solicited Event	152 (30.7)	28 (5.7)	11 (2.2)	191 (38.6)	31 (41.3)	4 (5.3)	0	35 (46.7)
Any Unsolicited Adverse Event	93 (18.8)	47 (9.5)	5 (1.0)	145 (29.3)	26 (34.7)	5 (6.7)	0	31 (41.3)



**Table S5. Antibody responses in 1-Dose Cohorts**

	Age 21 – 55										Age 56 – 80			
	1 µg (Cohort A) N=5		5 µg (Cohort B) N=10		7.5 µg (Cohort D1) N=5		10.0 µg (Cohort C) N=5		Pooled Placebo (Cohorts A, B, C, D1) N=10		7.5 µg (Cohort D2) N=5		Cohort D2 Placebo N=2	
Test/Time point	n	GMT (95% CI)	No	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)
<b>Luminex anti-S IgG</b>													2	
Day 1	5	274.0 (111.06, 676.22)	10	166.3 (86.17, 321.01)	5	207.5 (178.89, 240.80)	5	511.7 (61.69, 4244.31)	10	223.7 (126.60, 395.45)	5	141.0 (81.90, 242.68)	2	287.0 (NA)
Day 8	5	364.9 (151.09, 881.32)	10	277.1 (163.72, 468.84)	5	221.0 (145.26, 336.15)	5	995.4 (54.55, 18164.73)	10	278.1 (171.81, 450.11)	5	201.6 (117.94, 344.69)	2	398.1 (NA)
Day 15	5	757.8 (271.89, 2112.02)	10	2217.8 (888.14, 5538.12)	5	3698.4 (2628.51, 5203.68)	5	9482.5 (787.96, 114114.7)	10	267.1 (162.13, 440.09)	5	601.4 (135.44, 2670.21)	2	408.2 (NA)
Day 29	5	2130.0 (516.21, 8788.98)	10	4781.1 (2121.61, 10774.20)	5	13675.7 (6209.51, 30119.08)	5	32748.6 (4963.84, 216057.2)	10	236.5 (133.33, 419.49)	5	2333.3 (265.53, 20502.83)	2	392.7 (NA)

	Age 21 – 55										Age 56 – 80			
	1 µg (Cohort A) N=5		5 µg (Cohort B) N=10		7.5 µg (Cohort D1) N=5		10.0 µg (Cohort C) N=5		Pooled Placebo (Cohorts A, B, C, D1) N=10		7.5 µg (Cohort D2) N=5		Cohort D2 Placebo N=2	
Test/Time point	n	GMT (95% CI)	No	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)
Day 36	5	2542.6 (585.27, 11046.15)	10	4189.3 (2212.27, 7933.24)	5	14898.7 (5117.38, 43375.93)	5	26403.5 (5567.92, 125207.5)	10	289.4 (175.29, 477.68)	5	2119.5 (252.79, 17770.67)	2	330.5 (NA)
Day 43	5	2804.2 (680.03, 11563.45)	10	4958.6 (2484.11, 9898.07)	5	15480.5 (6111.05, 39215.12)	5	28763.3 (4965.70, 166608.3)	10	298.2 (171.99, 517.04)	5	2942.3 (477.76, 18120.22)	2	528.8 (NA)
Day 56	5	2734.4 (616.36, 12130.49)	10	3843.1 (1912.88, 7721.23)	5	13573.3 (4462.61, 41284.14)	5	21768.1 (3916.06, 121002.1)	10	297.2 (151.31, 583.74)	5	2490.5 (318.10, 19498.39)	2	415.0 (NA)
<b>Live Virus PRNT<sub>50</sub></b>														
Day 1	5	20.0 (20.00, 20.00)	10	20.0 (20.00, 20.00)	5	20.0 (20.00, 20.00)	5	20.0 (20.00, 20.00)	10	20.0 (20.00, 20.00)	5	20.0 (20.00, 20.00)	2	20.0 (NA)

	Age 21 – 55										Age 56 – 80			
	1 µg (Cohort A) N=5		5 µg (Cohort B) N=10		7.5 µg (Cohort D1) N=5		10.0 µg (Cohort C) N=5		Pooled Placebo (Cohorts A, B, C, D1) N=10		7.5 µg (Cohort D2) N=5		Cohort D2 Placebo N=2	
Test/Time point	n	GMT (95% CI)	No	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)
Day 29	5	20.0 (20.00, 20.00)	10	24.2 (19.50, 29.95)	5	27.7 (11.21, 68.46)	5	32.9 (14.73, 73.56)	10	20.9 (19.19, 22.68)	5	24.0 (18.61, 30.89)	2	20.0 (NA)
Day 57	5	20.0 (20.00, 20.00)	10	20.0 (20.00, 20.00)	5	20.0 (20.00, 20.00)	5	20.9 (18.48, 23.67)	10	20.0 (20.00, 20.00)	5	20.0 (20.00, 20.00)	2	20.0 (NA)
<b>Luminex anti-S IgM</b>														
Day 1	5	50.0 (50.00, 50.00)	10	73.5 (50.77, 106.51)	5	84.7 (44.63, 160.91)	5	77.9 (34.93, 173.82)	10	67.3 (47.40, 95.49)	5	53.0 (45.06, 62.37)	2	73.1 (NA)
Day 8	5	53.5 (44.37, 64.47)	10	73.6 (53.95, 100.50)	5	63.9 (42.06, 97.20)	5	140.1 (11.23, 1749.25)	10	63.3 (46.52, 86.06)	5	56.1 (40.74, 77.29)	2	116.4 (NA)

	Age 21 – 55										Age 56 – 80			
	1 µg (Cohort A) N=5		5 µg (Cohort B) N=10		7.5 µg (Cohort D1) N=5		10.0 µg (Cohort C) N=5		Pooled Placebo (Cohorts A, B, C, D1) N=10		7.5 µg (Cohort D2) N=5		Cohort D2 Placebo N=2	
Test/Time point	n	GMT (95% CI)	No	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)
Day 15	5	90.6 (28.15, 291.26)	10	427.0 (141.33, 1290.32)	5	215.4 (104.49, 443.91)	5	646.9 (99.38, 4211.00)	10	60.8 (42.94, 86.03)	5	171.1 (69.58, 420.93)	2	136.4 (NA)
<b>Luminex anti-S IgA</b>														
Day 1	5	383.1 (36.21, 4052.75)	10	142.1 (56.96, 354.28)	5	101.1 (52.46, 194.97)	5	236.1 (73.94, 754.10)	10	111.7 (86.18, 144.75)	5	61.5 (44.63, 84.76)	2	88.3 (NA)
Day 29	5	2119.1 (159.82, 28096.25)	10	1259.6 (336.74, 4711.46)	5	525.3 (159.82, 1726.38)	5	9056.6 (1083.57, 75696.55)	10	84.9 (64.26, 112.21)	5	321.7 (88.20, 1172.99)	2	162.9 (NA)
<b>Luminex anti- RBD IgG*</b>														

	Age 21 – 55										Age 56 – 80			
	1 µg (Cohort A) N=5		5 µg (Cohort B) N=10		7.5 µg (Cohort D1) N=5		10.0 µg (Cohort C) N=5		Pooled Placebo (Cohorts A, B, C, D1) N=10		7.5 µg (Cohort D2) N=5		Cohort D2 Placebo N=2	
Test/Time point	n	GMT (95% CI)	No	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)
Day 1			10	574 (467; 707)	5	631 (411; 969)			6	513 (340; 774)	5	510 (369; 705)	2	926 (8; 113760)
Day 29			10	2618 (1299; 5276)	5	3578 (1171; 10932)			6	653 (389; 1098)	5	1665 (717; 3869)	2	1113 (52; 23697)
<b>Luminex anti-NTD IgG*</b>														
Day 1			10	276 (242; 314)	5	269 (223; 326)			6	308 (198; 481)	5	269 (202; 357)	2	347 (61; 1964)
Day 29			10	443 (359; 548)	5	446 (260; 766)			6	323 (220; 474)	5	420 (290; 608)	2	309 (174; 549)

	Age 21 – 55										Age 56 – 80			
	1 µg (Cohort A) N=5		5 µg (Cohort B) N=10		7.5 µg (Cohort D1) N=5		10.0 µg (Cohort C) N=5		Pooled Placebo (Cohorts A, B, C, D1) N=10		7.5 µg (Cohort D2) N=5		Cohort D2 Placebo N=2	
Test/Time point	n	GMT (95% CI)	No	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)
Luminex anti-S2 IgG*														
Day 1			10	305 (156; 596)	5	204 (149; 279)			6	390 (144; 1055)		192 (116; 317)	2	276 (215; 356)
Day 29			10	9703 (3631; 25928)	5	55676 (18159; 170702)			6	380 (152; 953)		6520 (506; 83940)	2	270 (101; 725)

S = Full-Length SARS-CoV-2 Spike Protein; S2 = S2 domain of SARS-CoV-2 Spike Protein, RBD = receptor binding domain of SARS-CoV-2 Spike Protein; NTD =N-terminal domain of SARS-CoV-2 Spike Protein; PRNT =Plaque Reduction Neutralization Test; GMT=Geometric Mean Titer; CI=Confidence Interval;

N represents the total number of subjects in each cohort. n represents the number of subjects contributing to the summary.

\*IgG titers against RBD, NTD and S2 not assessed for subjects in Cohorts A and C.

**Table S6. Antibody responses in 2-Dose Cohorts**

	Age 21 – 55						Age 56 – 80					
Test/Time point	3 µg (Cohort F) N=12		5 µg (Cohort E) N=12		Cohorts E & F Pooled Placebo N=8		3 µg (Cohort H) N=12		5 µg (Cohort G) N=12		Cohorts G & H Pooled Placebo N=8	
	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)
<b>Luminex anti-S IgG</b>												
Day 1	12	261.9 (170.17, 403.15)	12	321.8 (244.70, 423.10)	8	251.8 (140.56, 451.18)	12	410.2 (221.33, 760.35)	12	334.4 (218.67, 511.27)	8	421.2 (286.14, 620.11)
Day 15	12	1894.6 (511.61, 7016.17)	12	1836.6 (1032.43, 3267.05)	8	201.0 (71.11, 568.04)	12	947.0 (342.52, 2618.17)	12	1423.6 (573.93, 3531.12)	8	339.2 (162.05, 710.14)
Day 29	12	5507.2 (1782.55, 17014.70)	12	5614.9 (3669.54, 8591.57)	8	299.1 (160.18, 558.63)	12	2450.7 (750.65, 8000.85)	12	8407.0 (3437.58, 20560.50)	8	266.2 (135.63, 522.46)
Day 36	12	5677.3 (1683.63, 19144.15)	12	7130.1 (4294.36, 11838.49)	8	215.2 (81.58, 567.53)	12	2971.1 (923.92, 9554.20)	12	7583.3 (3348.57, 17173.44)	8	381.6 (216.40, 672.96)

	Age 21 – 55						Age 56 – 80					
Test/Time point	3 µg (Cohort F) N=12		5 µg (Cohort E) N=12		Cohorts E & F Pooled Placebo N=8		3 µg (Cohort H) N=12		5 µg (Cohort G) N=12		Cohorts G & H Pooled Placebo N=8	
	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)
Day 43	12	14481.0 (6079.57, 34492.51)	12	16771.9 (10507.27 , 26771.56)	8	232.4 (109.91, 491.39)	12	5085.5 (1348.87, 19173.26)	12	16513.5 (7432.56, 36689.28)	8	335.8 (128.80, 875.63)
Day 57	12	13079.9 (5068.41, 33755.04)	12	16558.1 (9486.89, 28899.99)	8	360.0 (189.44, 684.30)	12	5903.9 (1967.62, 17714.81)	12	10375.4 (5580.18, 19291.17)	8	386.4 (200.55, 744.63)
Day 85	12	9526.0 (4090.22, 22185.61)	12	11592.6 (6630.05, 20269.63)	8	265.9 (113.09, 625.08)	12	5463.5 (2085.67, 14312.11)	12	11998.1 (5247.08, 27435.30)	8	421.1 (205.39, 863.45)



	Age 21 – 55						Age 56 – 80					
Test/Time point	3 µg (Cohort F) N=12		5 µg (Cohort E) N=12		Cohorts E & F Pooled Placebo N=8		3 µg (Cohort H) N=12		5 µg (Cohort G) N=12		Cohorts G & H Pooled Placebo N=8	
	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)
<b>Live Virus PRNT<sub>50</sub></b>												
Day 1	12	20.0 (20.00, 20.00)	12	20.0 (20.00, 20.00)	8	20.0 (20.00, 20.00)	12	20.0 (20.00, 20.00)	12	20.0 (20.00, 20.00)	8	20.0 (20.00, 20.00)
Day 29	12	27.3 17.41, 42.84)	12	29.3 (23.09, 37.13)	8	20.0 (20.00, 20.00)	12	22.5 (19.47, 26.10)	12	20.6 (19.34, 21.88)	8	20.0 (20.00, 20.00)
Day 43	12	34.9 (24.14, 50.38)	12	51.8 (32.30, 83.21)	8	20.0 (20.00, 20.00)	12	27.1 (15.17, 48.35)	12	24.0 (20.56, 27.95)	8	20.0 (20.00, 20.00)
Day 57	12	23.8 (17.39, 32.47)	12	36.0 (24.32, 53.16)	8	20.0 (20.00, 20.00)	12	29.7 (15.63, 56.37)	12	20.4 (19.71, 21.09)	8	20.0 (20.00, 20.00)

	Age 21 – 55						Age 56 – 80					
Test/Time point	3 µg (Cohort F) N=12		5 µg (Cohort E) N=12		Cohorts E & F Pooled Placebo N=8		3 µg (Cohort H) N=12		5 µg (Cohort G) N=12		Cohorts G & H Pooled Placebo N=8	
	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)
Day 85	11	24.4 (17.88, 33.30)	12	25.0 (18.94, 33.06)	8	20.0 (20.00, 20.00)	11	27.0 (16.51, 44.13)	12	20.0 (20.00, 20.00)	8	20.0 (20.00, 20.00)
<b>Luminex anti-S IgM</b>												
Day 1	12	61.5 (42.99, 88.04)	12	62.6 (50.74, 77.19)	8	71.8 (52.43, 98.23)	12	83.1 (60.16, 114.66)	12	62.7 (47.16, 83.40)	8	59.2 (42.82, 81.82)
Day 15	12	222.7 (108.47, 457.22)	12	194.5 (128.76, 293.83)	8	60.7 (38.50, 95.81)	12	145.1 (64.55, 326.32)	12	114.1 (65.55, 198.53)	8	54.3 (45.75, 64.53)

	Age 21 – 55						Age 56 – 80					
Test/Time point	3 µg (Cohort F) N=12		5 µg (Cohort E) N=12		Cohorts E & F Pooled Placebo N=8		3 µg (Cohort H) N=12		5 µg (Cohort G) N=12		Cohorts G & H Pooled Placebo N=8	
	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)
<b>Luminex anti-S IgA</b>												
Day 1	12	149.2 (111.02, 200.55)	12	107.1 (79.89, 143.45)	8	164.9 (119.89, 226.68)	12	182.4 (93.43, 356.08)	12	127.7 (99.85, 163.38)	8	225.2 (157.52, 322.02)
Day 29	12	704.6 (445.38, 1114.72)	12	413.6 (255.87, 668.45)	8	186.4 (129.55, 268.28)	12	853.5 (278.06, 2619.52)	12	619.8 (186.82, 2056.61)	8	174.0 (85.99, 352.00)
Day 57	12	519.8 (306.07, 882.76)	12	631.8 (364.71, 1094.58)	8	121.6 (86.83, 170.31)	12	1034.3 (325.44, 3287.32)	12	1174.9 (341.39, 4043.68)	8	250.5 (137.70, 455.66)

	Age 21 – 55						Age 56 – 80					
Test/Time point	3 µg (Cohort F) N=12		5 µg (Cohort E) N=12		Cohorts E & F Pooled Placebo N=8		3 µg (Cohort H) N=12		5 µg (Cohort G) N=12		Cohorts G & H Pooled Placebo N=8	
	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)
<b>Luminex anti- RBD IgG*</b>												
Day 1			12	648 (480, 876)	4	731 (329, 1624)			12	506 (430, 596)	4	580 (417, 806)
Day 29			12	1606 (1227, 2103)	4	672 (632, 714)			12	1048 (696, 1579)	4	649 (378, 1114)
Day 57			12	4211 (2665, 6656)	4	505 (402, 634)			12	3190 (1744, 5833)	4	798 (553, 1151)

	Age 21 – 55						Age 56 – 80					
Test/Time point	3 µg (Cohort F) N=12		5 µg (Cohort E) N=12		Cohorts E & F Pooled Placebo N=8		3 µg (Cohort H) N=12		5 µg (Cohort G) N=12		Cohorts G & H Pooled Placebo N=8	
	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)
<b>Luminex anti-NTD IgG*</b>												
Day 1			12	466 (296, 731)	4	600 (211, 1709)			12	468 (377, 581)	4	519 (260, 1034)
Day 29			12	862 (746, 995)	4	643 (611, 676)			12	569 (441, 734)	4	567 (353, 913)
Day 57			12	1169 (923, 1479)	4	505 (416, 614)			12	1083 (781, 1502)	4	747 (497, 1124)


Test/Time point	Age 21 – 55						Age 56 – 80					
	3 µg (Cohort F) N=12		5 µg (Cohort E) N=12		Cohorts E & F Pooled Placebo N=8		3 µg (Cohort H) N=12		5 µg (Cohort G) N=12		Cohorts G & H Pooled Placebo N=8	
	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)
<b>Luminex anti-S2 IgG*</b>												
Day 1			12	590 (334, 1045)	4	1255 (937, 1681)			12	503 (374, 678)	4	486 (234, 1010)
Day 29			12	9262 (5455, 15724)	4	1238 (447, 3430)			12	10133 (5034, 20396)	4	546 (410, 726)
Day 57			12	15272 (7489, 31144)	4	1049 (361, 3045)			12	22794 (13235, 39258)	4	798 (675, 944)

S = Full-Length SARS-CoV-2 Spike Protein; S2 = S2 domain of SARS-CoV-2 Spike Protein, RBD = receptor binding domain of SARS-CoV-2 Spike Protein; NTD =N-terminal domain of SARS-CoV-2 Spike Protein; PRNT =Plaque Reduction Neutralization Test; GMT=Geometric Mean Titer; CI=Confidence Interval;

	Age 21 – 55						Age 56 – 80					
Test/Time point	3 µg (Cohort F) N=12		5 µg (Cohort E) N=12		Cohorts E & F Pooled Placebo N=8		3 µg (Cohort H) N=12		5 µg (Cohort G) N=12		Cohorts G & H Pooled Placebo N=8	
	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)

N represents the total number of subjects in each cohort. n represents the number of subjects contributing to the summary.


\*IgG titers against RBD, NTD and S2 were not assessed for subjects in cohorts F and H.




**Figure S1. Spike location of the peptide pools used in the cellular assays.**



### A. YA cohorts (21-55 yrs)




### B. OA cohorts (56-80 yrs)




**Figure S2. ELISPOT responses by tested peptide pool in 1 dose cohorts.**

ELISPOT results on study days 1, 15, 29 and/or 57 are presented as spot forming cells (SFC) per  $10^6$  PBMCs are displayed for single dose cohorts of younger adults (YA) (Panel A) and older adults (OA) (Panel B). Note that day 29 data is only for Cohorts A and B. Bar graphs display data as mean per group with error bars depicting the standard deviation (SD). Each dot represents an individual participant.

**A. YA cohorts (21-55 yrs)**




**B. OA cohorts (56-80 yrs)**




**Figure S3. ELISPOT responses by tested peptide pool in 2 dose cohorts.**

ELISPOT results are presented as spot forming cells (SFC) per 10<sup>6</sup> PBMCs are displayed for two-dose cohorts of younger adults (YA) (Panel A) and older adults (OA) (Panel B). Bar graphs display data as mean per group with error bars depicting the standard deviation (SD). Each dot represents an individual participant.

## A) One-Dose Cohorts




## B) Two-Dose Cohorts




**Figure S4. Antigen-specific IFN $\gamma$  CD8 T cell responses by ICS.**

Total antigen-specific IFN $\gamma$  responses in CD8 T cells following stimulation with Spike peptide pools are presented for one-dose (Panel A) and two-dose (Panel B) cohorts. Horizontal bar displays mean per group with error bars depicting the standard deviation (SD). Each dot represents an individual participant. Younger adults 21-55 years; older adults 56-80 years.

### A) One-Dose Cohorts




### B) Two-Dose Cohorts




**Figure S5. Antigen-specific IFN $\gamma$  CD4 T cell responses by ICS.**

Total antigen-specific IFN $\gamma$  responses in CD4 T cells following stimulation with Spike peptide pools are presented for one-dose (Panel A) and two-dose (Panel B) cohorts. Horizontal bar displays mean per group with error bars depicting the standard deviation (SD). Each dot represents an individual participant. Younger adults 21-55 years; older adults 56-80 years.

## A) One-Dose Cohorts



## B) Two-Dose Cohorts



**Figure S6. Antigen-specific IFN $\gamma$  and IL4 CD4 T cell responses by ICS.**

Total antigen-specific IFN $\gamma$  and IL4 responses in CD4 T cells following stimulation with Spike peptide pools were measured to assess Th1 responses. Figure presents data for one-dose (Panel A) and two-dose (Panel B) cohorts. Horizontal bar displays mean per group with error bars depicting the standard deviation (SD). Each dot represents an individual participant. Younger adults 21-55 years; older adults 56-80 years.